| A palliative approach for heart failure end-of-life care |
11 |
| Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types |
10 |
| The long noncoding RNA landscape in cardiovascular disease: a brief update |
10 |
| Machine learning in heart failure: ready for prime time |
10 |
| Altered branched chain amino acid metabolism: toward a unifying cardiometabolic hypothesis |
9 |
| Viral myocarditis: a prime example for endomyocardial biopsy-guided diagnosis and therapy |
9 |
| Genetic cardiomyopathies |
9 |
| Blood, tissue and imaging biomarkers in calcific aortic valve stenosis: past, present and future |
8 |
| Long-lasting benefits of exercise for those living with a Fontan circulation |
8 |
| Physical activity and fitness for the prevention of hypertension |
8 |
| Polygenic risk scores in coronary artery disease |
7 |
| Statin loading in cardiovascular surgery: never too early to treat |
7 |
| The role of diet for prevention and management of hypertension |
7 |
| The role of the pharmacist in hypertension management |
7 |
| Extracellular vesicles in cardiovascular homeostasis and disease |
7 |
| Cardiovascular risk reduction with icosapent ethyl |
7 |
| Genetic basis of arrhythmogenic cardiomyopathy |
6 |
| Endocarditis in the setting of IDU: multidisciplinary management |
6 |
| See one, simulate many, do one, teach one: cardiac surgical simulation |
6 |
| Noncoding RNAs in cardiovascular diseases |
5 |
| Mean platelet volume and coronary artery disease |
5 |
| Hyperuricaemia and vascular risk: the debate continues |
5 |
| Left atrial strain: measurement and clinical application |
5 |
| Ischemic stroke in young adults |
5 |
| Myocarditis and cardiomyopathy |
5 |
| Diagnosis and clinical management of long-QT syndrome |
5 |
| Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists |
5 |
| Immune checkpoint inhibitor myocarditis |
4 |
| Spontaneous coronary artery dissection: update 2019 |
4 |
| Genetics of early-onset coronary artery disease: from discovery to clinical translation |
4 |
| Iron overload cardiomyopathy: from diagnosis to management |
4 |
| Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes: a pathophysiology-based review of clinical implications |
4 |
| SGLT2 inhibitors: practical considerations and recommendations for cardiologists |
4 |
| Adriamycin-associated cardiomyopathy: where are we now? updates in pathophysiology, dose recommendations, prognosis, and outcomes |
4 |
| Assessment of myocardial viability using single-photon emission computed tomography myocardial perfusion imaging |
4 |
| Predictors of heart failure development in type 2 diabetes: a practical approach |
4 |
| Telomere length and cardiovascular disease risk |
3 |
| Sex differences in hypertrophic cardiomyopathy: new insights |
3 |
| Frequent premature ventricular beats in healthy children: when to ignore and when to treat? |
3 |
| Applications of left ventricular strain measurements to patients undergoing chemotherapy |
3 |
| Left ventricular assist device as destination therapy for end stage heart failure: the right time for the right patients |
3 |
| Developing a mitral valve center of excellence |
3 |
| Mitral repair and the robot: a revolutionary tool or marketing ploy? |
3 |
| Transcatheter device closure of atrial septal defects: more to think about than just closing the hole |
3 |
| Acute kidney injury in congenital heart disease |
3 |
| Orthostatic hypotension for the cardiologist |
3 |
| Genetics of atrial fibrillation: an update |
3 |
| Vitamin D supplements and prevention of cardiovascular disease |
3 |
| Management of patients with end-stage renal disease: coronary artery bypass graft surgery versus percutaneous coronary intervention |
3 |
| Sex-specific risk factors for cardiovascular disease in women-making cardiovascular disease real |
3 |
